文献速递血液净化与透析肾移植

丙肝抗体阳性维持性透析患者的死亡与肾移植结局:回顾性队列研究

Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study.
PubMed 文献 · Am J Kidney Dis · 2019-01-29

该回顾性队列研究纳入2004至2014年美国一家全国性透析机构的442,171例成年长期透析患者,其中31,624例(7.2%)HCV抗体阳性。HCV抗体阳性与全因死亡风险轻度升高相关(aHR 1.09,95%CI 1.07-1.11),且进入肾移植等待名单的比例显著降低(sHR 0.67,95%CI 0.61-0.74);但一旦进入等待名单,移植率与阴性患者无差异(sHR 1.10,95%CI 0.96-1.27)。HCV阳性患者接受移植后生存获益显著(3年aHR 0.42,95%CI 0.27-0.63),接受HCV阳性供肾在移植后2年时较继续等待HCV阴性肾有生存优势。

要点

  • HCV抗体阳性透析患者死亡风险轻度升高(aHR 1.09),进入移植等待名单比例显著降低(sHR 0.67)。
  • 一旦进入等待名单,HCV阳性与阴性患者的肾移植率无显著差异(sHR 1.10,95%CI 0.96-1.27)。
  • HCV阳性患者接受移植较继续透析显著改善生存(3年aHR 0.42),接受HCV阳性供肾在2年时即有生存优势。

核心结论

  • HCV抗体阳性透析患者进入肾移植等待名单的比例显著低于阴性患者,但移植后生存获益显著。
  • HCV抗体阳性患者可考虑暂缓HCV治疗而接受HCV感染供肾,以促进移植并延长生存。

研究设计与样本

  • 暴露为HCV抗体血清状态,通过临床数据获取;结局包括透析死亡率、进入等待名单、肾移植及移植生存获益。
  • 将临床数据与器官获取和移植网络数据链接,采用Cox回归和病因特异性风险回归分析。

主要发现

  • 442,171例透析患者中31,624例(7.2%)为HCV抗体阳性。
  • HCV抗体阳性与死亡风险轻度升高相关(aHR 1.09,95%CI 1.07-1.11)。
  • HCV抗体阳性与进入肾移植等待名单比例显著降低相关(sHR 0.67,95%CI 0.61-0.74)。
  • 进入等待名单后,HCV阳性与阴性患者的肾移植率无显著差异(sHR 1.10,95%CI 0.96-1.27)。
  • HCV阳性患者接受移植后3年生存获益显著(aHR 0.42,95%CI 0.27-0.63);接受HCV阳性供肾在移植后2年时较继续等待HCV阴性肾有生存优势。

临床怎么用

  • 对HCV抗体阳性透析患者应积极评估肾移植,避免因HCV阳性而推迟等待名单登记。
  • 可考虑让HCV抗体阳性患者接受HCV感染供肾以缩短等待时间并获得生存获益。
  • 在等待移植期间是否暂缓HCV治疗需个体化权衡,以促进移植并延长生存。

局限性

  • 缺乏HCV病毒载量和肝活检数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Hepatitis C virus (HCV) infection is common among maintenance dialysis patients. Few studies have examined both dialysis survival and transplantation outcomes for HCV-seropositive patients because registry data sets lack information for HCV serostatus. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: Adult long-term dialysis patients treated by a US national dialysis provider between January 1, 2004, and December 31, 2014. EXPOSURE: HCV antibody serostatus obtained as part of clinical data from a national dialysis provider. OUTCOMES: Mortality on dialysis therapy, entry onto the kidney transplant waiting list, kidney transplantation, and estimated survival benefit from kidney transplantation versus remaining on the waitlist. ANALYTICAL APPROACH: After linking clinical data with data from the Organ Procurement and Transplantation Network, Cox and cause-specific hazards regression were implemented to estimate the associations between HCV seropositivity and mortality, as well as entry onto the kidney transplant waitlist. Cox regression was also used to estimate the survival benefit from transplantation versus dialysis among HCV-seropositive individuals. RESULTS: Among 442,171 dialysis patients, 31,624 (7.2%) were HCV seropositive. HCV seropositivity was associated with a small elevation in the rate of death (adjusted HR [aHR], 1.09; 95% CI, 1.07-1.11) and a substantially lower rate of entry onto the kidney transplant waitlist (subdistribution HR [sHR], 0.67; 95% CI, 0.61-0.74). Once wait-listed, the kidney transplantation rate was not different for HCV-seropositive (sHR 1.10; 95% CI, 0.96-1.27) versus HCV-seronegative patients. HCV-seropositive patients lived longer with transplantation (aHR at 3 years, 0.42; 95% CI, 0.27-0.63). Receiving an HCV-seropositive donor kidney provided a survival advantage at the 2-year posttransplantation time point compared to remaining on dialysis therapy waiting for an HCV-negative kidney. LIMITATIONS: No data for HCV viral load or liver biopsy. CONCLUSIONS: HCV-seropositive patients experience reduced access to the kidney transplantation waitlist despite deriving a substantial survival benefit from transplantation. HCV-seropositive patients should consider foregoing HCV treatment while accepting kidneys from HCV-infected donors to facilitate transplantation and prolong survival.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Sawinski D, Forde KA, Lo Re V, et al. Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study. Am J Kidney Dis. 2019. PMID: 30704882. doi:10.1053/j.ajkd.2018.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。